These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 18094216)

  • 1. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.
    Garnett CE; Beasley N; Bhattaram VA; Jadhav PR; Madabushi R; Stockbridge N; Tornøe CW; Wang Y; Zhu H; Gobburu JV
    J Clin Pharmacol; 2008 Jan; 48(1):13-8. PubMed ID: 18094216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?
    Shah RR
    Pharmacol Ther; 2008 Aug; 119(2):215-21. PubMed ID: 18455801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
    Rock EP; Finkle J; Fingert HJ; Booth BP; Garnett CE; Grant S; Justice RL; Kovacs RJ; Kowey PR; Rodriguez I; Sanhai WR; Strnadova C; Targum SL; Tsong Y; Uhl K; Stockbridge N
    Am Heart J; 2009 May; 157(5):827-36, 836.e1. PubMed ID: 19376308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A perspective on the use of concentration-QT modeling in drug development.
    Russell T; Riley SP; Cook JA; Lalonde RL
    J Clin Pharmacol; 2008 Jan; 48(1):9-12. PubMed ID: 18094215
    [No Abstract]   [Full Text] [Related]  

  • 6. Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates.
    Bloomfield D; Krishna R
    J Clin Pharmacol; 2008 Jan; 48(1):6-8. PubMed ID: 18094214
    [No Abstract]   [Full Text] [Related]  

  • 7. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical issues including design and sample size calculation in thorough QT/QTc studies.
    Zhang J; Machado SG
    J Biopharm Stat; 2008; 18(3):451-67. PubMed ID: 18470755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creation of a knowledge management system for QT analyses.
    Tornøe CW; Garnett CE; Wang Y; Florian J; Li M; Gobburu JV
    J Clin Pharmacol; 2011 Jul; 51(7):1035-42. PubMed ID: 20978278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-response modeling approach for assessing QT effect in "thorough" QT/QTc studies.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2010 May; 20(3):615-31. PubMed ID: 20358440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
    Shah RR
    Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance characteristics for some typical QT study designs under the ICH E-14 guidance.
    Hutmacher MM; Chapel S; Agin MA; Fleishaker JC; Lalonde RL
    J Clin Pharmacol; 2008 Feb; 48(2):215-24. PubMed ID: 18199896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size calculations in thorough QT studies.
    Zhang L; Dmitrienko A; Luta G
    J Biopharm Stat; 2008; 18(3):468-82. PubMed ID: 18470756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of ANOVA to estimate inter- and intra-reader variability for a group of readers in thorough QT/QTc studies.
    Natekar M; Mahajan V; Satra A; O'Kelly M; Karnad DR
    Clin Pharmacol Ther; 2008 Mar; 83(3):489-91. PubMed ID: 18183035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct.
    Hondeghem LM
    Eur J Pharmacol; 2008 Apr; 584(1):1-9. PubMed ID: 18304526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies.
    Shah RR; Morganroth J; Kleiman RB
    Br J Clin Pharmacol; 2015 Mar; 79(3):456-64. PubMed ID: 25060671
    [No Abstract]   [Full Text] [Related]  

  • 17. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
    Cheng B; Chow SC; Burt D; Cosmatos D
    J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.
    Salvi V; Karnad DR; Panicker GK; Kothari S
    Br J Pharmacol; 2010 Jan; 159(1):34-48. PubMed ID: 19775279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs, QT interval prolongation and ICH E14: the need to get it right.
    Shah RR
    Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed effects in the exposure-response analysis of clinical QTc trials.
    Glomb P; Ring A
    J Biopharm Stat; 2012; 22(2):387-400. PubMed ID: 22251181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.